Arcturus Therapeutics Holdings Financial Statements (ARCT)
|
|
|
|
Report date
|
|
|
31.12.2023 |
14.03.2024 |
08.05.2024 |
05.08.2024 |
07.11.2024 |
|
07.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
34.0 |
28.2 |
32.6 |
46.0 |
41.7 |
|
148.5 |
|
Operating Income, bln rub |
|
|
-15.1 |
-11.1 |
-30.4 |
-2.68 |
-10.7 |
|
-54.9 |
|
EBITDA, bln rub |
? |
|
-15.1 |
-7.49 |
-25.5 |
-16.5 |
-9.83 |
|
-59.3 |
|
Net profit, bln rub |
? |
|
-8.57 |
-8.57 |
-26.8 |
-17.2 |
-6.90 |
|
-59.5 |
|
|
OCF, bln rub |
? |
|
|
-0.545 |
-5.56 |
-29.8 |
-24.1 |
|
-60.0 |
|
CAPEX, bln rub |
? |
|
|
0.837 |
0.240 |
0.323 |
0.563 |
|
1.96 |
|
FCF, bln rub |
? |
|
|
-1.38 |
-5.80 |
-30.2 |
-23.5 |
|
-60.8 |
|
Dividend payout, bln rub
|
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
49.1 |
38.5 |
63.0 |
47.8 |
49.6 |
|
198.8 |
|
Cost of production, bln rub |
|
|
0.000 |
0.815 |
5.41 |
0.900 |
0.000 |
|
7.13 |
|
R&D, bln rub |
|
|
36.6 |
26.8 |
53.6 |
36.3 |
39.1 |
|
155.9 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.004 |
0.000 |
0.000 |
0.000 |
|
0.004 |
|
|
Assets, bln rub |
|
|
429.4 |
429.4 |
418.8 |
388.6 |
370.7 |
|
370.7 |
|
Net Assets, bln rub |
? |
|
281.6 |
278.5 |
264.0 |
258.6 |
261.9 |
|
261.9 |
|
Debt, bln rub |
|
|
25.9 |
30.2 |
31.9 |
30.9 |
26.0 |
|
26.0 |
|
Cash, bln rub |
|
|
347.0 |
347.0 |
288.4 |
315.3 |
237.2 |
|
237.2 |
|
Net debt, bln rub |
|
|
-321.1 |
-316.8 |
-256.5 |
-284.4 |
-211.2 |
|
-211.2 |
|
|
Ordinary share price, rub |
|
|
31.5 |
31.5 |
33.8 |
24.4 |
23.2 |
|
19.0 |
|
Number of ordinary shares, mln |
|
|
26.6 |
26.6 |
26.9 |
27.0 |
27.1 |
|
27.1 |
|
|
Market cap, bln rub |
|
|
840 |
840 |
908 |
657 |
628 |
|
514 |
|
EV, bln rub |
? |
|
518 |
523 |
651 |
372 |
417 |
|
302 |
|
Book value, bln rub |
|
|
282 |
279 |
264 |
259 |
262 |
|
262 |
|
|
EPS, rub |
? |
|
-0.32 |
-0.32 |
-1.00 |
-0.64 |
-0.26 |
|
-2.20 |
|
FCF/share, rub |
|
|
0.00 |
-0.05 |
-0.22 |
-1.12 |
-0.87 |
|
-2.25 |
|
BV/share, rub |
|
|
10.6 |
10.5 |
9.82 |
9.59 |
9.68 |
|
9.68 |
|
|
EBITDA margin, % |
? |
|
-44.5% |
-26.6% |
-78.4% |
-35.8% |
-23.6% |
|
-40.0% |
|
Net margin, % |
? |
|
-25.2% |
-30.4% |
-82.3% |
-37.4% |
-16.6% |
|
-40.1% |
|
FCF yield, % |
? |
|
-2.32% |
-2.49% |
1.09% |
-10.8% |
-9.69% |
|
-11.8% |
|
ROE, % |
? |
|
-9.44% |
-9.55% |
-39.5% |
-26.6% |
-22.7% |
|
-22.7% |
|
ROA, % |
? |
|
-6.19% |
-6.19% |
-24.9% |
-17.7% |
-16.1% |
|
-16.1% |
|
|
P/E |
? |
|
-31.6 |
-31.6 |
-8.71 |
-9.54 |
-10.6 |
|
-8.63 |
|
P/FCF |
|
|
-43.1 |
-40.2 |
91.8 |
-9.28 |
-10.3 |
|
-8.44 |
|
P/S |
? |
|
5.04 |
5.22 |
7.98 |
4.37 |
4.23 |
|
3.46 |
|
P/BV |
? |
|
2.98 |
3.01 |
3.44 |
2.54 |
2.40 |
|
1.96 |
|
EV/EBITDA |
? |
|
-4.95 |
-5.67 |
-6.58 |
-5.81 |
-7.03 |
|
-5.10 |
|
Debt/EBITDA |
|
|
3.07 |
3.43 |
2.59 |
4.44 |
3.56 |
|
3.56 |
|
|
R&D/CAPEX, % |
|
|
|
3 204% |
22 322% |
11 239% |
6 947% |
|
7 937% |
|
|
CAPEX/Revenue, % |
|
|
0.00% |
2.97% |
0.74% |
0.70% |
1.35% |
|
1.32% |
|
| Arcturus Therapeutics Holdings shareholders |
